vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $196.0M, roughly 1.0× Axsome Therapeutics, Inc.). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs -14.6%, a 22.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 12.9%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 19.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
AXSM vs COLL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $205.4M |
| Net Profit | $-28.6M | $17.0M |
| Gross Margin | — | 62.5% |
| Operating Margin | -13.8% | 29.6% |
| Net Margin | -14.6% | 8.3% |
| Revenue YoY | 65.0% | 12.9% |
| Net Profit YoY | 61.9% | 35.3% |
| EPS (diluted) | $-0.55 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $205.4M | ||
| Q3 25 | $171.0M | $209.4M | ||
| Q2 25 | $150.0M | $188.0M | ||
| Q1 25 | $121.5M | $177.8M | ||
| Q4 24 | $118.8M | $181.9M | ||
| Q3 24 | $104.8M | $159.3M | ||
| Q2 24 | $87.2M | $145.3M | ||
| Q1 24 | $75.0M | $144.9M |
| Q4 25 | $-28.6M | $17.0M | ||
| Q3 25 | $-47.2M | $31.5M | ||
| Q2 25 | $-48.0M | $12.0M | ||
| Q1 25 | $-59.4M | $2.4M | ||
| Q4 24 | $-74.9M | $12.5M | ||
| Q3 24 | $-64.6M | $9.3M | ||
| Q2 24 | $-79.3M | $19.6M | ||
| Q1 24 | $-68.4M | $27.7M |
| Q4 25 | — | 62.5% | ||
| Q3 25 | — | 61.7% | ||
| Q2 25 | — | 57.7% | ||
| Q1 25 | — | 54.8% | ||
| Q4 24 | — | 54.0% | ||
| Q3 24 | — | 60.8% | ||
| Q2 24 | — | 62.5% | ||
| Q1 24 | — | 63.1% |
| Q4 25 | -13.8% | 29.6% | ||
| Q3 25 | -27.0% | 29.7% | ||
| Q2 25 | -24.5% | 18.7% | ||
| Q1 25 | -46.9% | 12.2% | ||
| Q4 24 | -61.1% | 20.9% | ||
| Q3 24 | -59.8% | 21.9% | ||
| Q2 24 | -89.5% | 32.7% | ||
| Q1 24 | -89.7% | 34.1% |
| Q4 25 | -14.6% | 8.3% | ||
| Q3 25 | -27.6% | 15.0% | ||
| Q2 25 | -32.0% | 6.4% | ||
| Q1 25 | -48.9% | 1.4% | ||
| Q4 24 | -63.1% | 6.9% | ||
| Q3 24 | -61.7% | 5.9% | ||
| Q2 24 | -91.0% | 13.5% | ||
| Q1 24 | -91.1% | 19.1% |
| Q4 25 | $-0.55 | $0.48 | ||
| Q3 25 | $-0.94 | $0.84 | ||
| Q2 25 | $-0.97 | $0.34 | ||
| Q1 25 | $-1.22 | $0.07 | ||
| Q4 24 | $-1.54 | $0.36 | ||
| Q3 24 | $-1.34 | $0.27 | ||
| Q2 24 | $-1.67 | $0.52 | ||
| Q1 24 | $-1.44 | $0.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $301.7M |
| Total Assets | $689.8M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $386.7M | ||
| Q3 25 | $325.3M | $285.9M | ||
| Q2 25 | $303.0M | $222.2M | ||
| Q1 25 | $300.9M | $197.8M | ||
| Q4 24 | $315.4M | $162.8M | ||
| Q3 24 | $327.3M | $120.0M | ||
| Q2 24 | $315.7M | $271.6M | ||
| Q1 24 | $331.4M | $318.0M |
| Q4 25 | $88.3M | $301.7M | ||
| Q3 25 | $73.7M | $274.8M | ||
| Q2 25 | $73.1M | $232.2M | ||
| Q1 25 | $53.2M | $234.4M | ||
| Q4 24 | $57.0M | $228.8M | ||
| Q3 24 | $92.9M | $234.3M | ||
| Q2 24 | $102.9M | $216.6M | ||
| Q1 24 | $144.0M | $222.2M |
| Q4 25 | $689.8M | $1.7B | ||
| Q3 25 | $669.3M | $1.6B | ||
| Q2 25 | $639.8M | $1.6B | ||
| Q1 25 | $596.7M | $1.6B | ||
| Q4 24 | $568.5M | $1.7B | ||
| Q3 24 | $561.5M | $1.6B | ||
| Q2 24 | $548.2M | $1.1B | ||
| Q1 24 | $545.7M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $123.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $122.4M |
| FCF MarginFCF / Revenue | -9.6% | 59.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $123.0M | ||
| Q3 25 | $1.0M | $78.4M | ||
| Q2 25 | $-32.4M | $72.4M | ||
| Q1 25 | $-43.4M | $55.4M | ||
| Q4 24 | $-26.2M | $84.6M | ||
| Q3 24 | $-18.6M | $-9.0M | ||
| Q2 24 | $-30.1M | $67.4M | ||
| Q1 24 | $-53.5M | $61.9M |
| Q4 25 | $-18.7M | $122.4M | ||
| Q3 25 | $988.0K | $78.3M | ||
| Q2 25 | $-32.4M | $72.4M | ||
| Q1 25 | $-43.7M | $54.6M | ||
| Q4 24 | $-26.2M | $84.1M | ||
| Q3 24 | $-18.7M | $-9.2M | ||
| Q2 24 | $-30.2M | $67.1M | ||
| Q1 24 | $-53.6M | $61.4M |
| Q4 25 | -9.6% | 59.6% | ||
| Q3 25 | 0.6% | 37.4% | ||
| Q2 25 | -21.6% | 38.5% | ||
| Q1 25 | -36.0% | 30.7% | ||
| Q4 24 | -22.1% | 46.2% | ||
| Q3 24 | -17.9% | -5.8% | ||
| Q2 24 | -34.6% | 46.2% | ||
| Q1 24 | -71.4% | 42.3% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.3% | 0.4% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.1% | 0.2% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 0.1% | 0.4% |
| Q4 25 | — | 7.25× | ||
| Q3 25 | — | 2.49× | ||
| Q2 25 | — | 6.05× | ||
| Q1 25 | — | 22.92× | ||
| Q4 24 | — | 6.75× | ||
| Q3 24 | — | -0.96× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 2.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
